Drug Pipeline

Fluctuations in drug pricing and medication shortages are among the reasons for rising drug prices. Learn how you can protect your hospital’s bottom line.

Albert A. Rizzo, MD, senior medical advisor for the American Lung Association, says the increasing number of drugs in the pipeline could improve airflow and address the underlying disease process.

Education is a significant element of comprehensive care for COPD patients. In this Q&A, one expert shares her recommendations.

Finding technology solutions to diagnose and manage chronic conditions is critical to the future of healthcare.

Key takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.

FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.

A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.

CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.

Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?

External, non-payer generated data can inform formulary decision-making-if payers know their strengths and weaknesses.

The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.

Value-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.

Recent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.

Acute myeloid leukemia experts share promising new developments on the oncology horizon.

Recent study findings reveal which patients are more likely to be readmitted for COPD problems, and which readmission reduction strategies might work best.

To succeed as a Next Generation ACO, Indiana University Health system is changing its COPD care management approach.

Physicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.

PBMs partnering with pharmacies and drug makers may have a solution to nonadherence due to high pharma costs.

There are several possible reasons that breastfeeding may influence breast cancer risk, according to the American Institute of Cancer Research. Find out what they are.

New research shows that these certain patients with breast cancer can benefit from genetic testing for all breast cancer genes.

The medication’s ability to reduce inflammation sited as one possible explanation.

Study highlights the need for services and research for this understudied population.

Study shows Clovis Oncology’s rucaparib shows clinically meaningful impact in delaying disease recurrence in ovarian cancer.

Understanding genetic variations and tumor differences in black women with breast cancer could lead to personalized diagnosis and treatment.

A new study found that distinguishing between population health and community health strategies can help health organizations define clear goals and earmark the right resources to accomplish them.